

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1069)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION MEMORANDUM

This announcement is made by China Health Technology Group Holding Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

STRATEGIC COOPERATION MEMORANDUM

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 16 May 2024, the Company entered into a non-legally effective and binding strategic cooperation memorandum (the “**Strategic Cooperation Memorandum**”) with Fujian Ningde Sikula Technology Co., Ltd.* (福建寧德斯庫拉科技有限公司) (“**Sikula**”), pursuant to which both parties agreed to cooperate in joint research, development, and sale of ginseng extraction ionized energy water in the People’s Republic of China (the “**PRC**”) (the “**Cooperation Business**”).

The Company is an investment holding company and its subsidiaries are principally engaged in forestry management, ginseng plantation and trading in the PRC.

Sikula is a company established in the PRC with limited liability and is principally engaged in the research and development and sale of ginseng extraction ionized energy water, wholesale and retail of edible agricultural products, and purchase and sale of primary agricultural products.

Pursuant to the Strategic Cooperation Memorandum, in order to jointly develop the Cooperation Business, the Company, with its strengths in ginseng plantation and sales business, will strengthen the exchange and collaboration with Sikula in various aspects such as research and development of ginseng extraction technology and sales for mutual complementary and sharing purposes.

Both parties will enter into a definitive agreement in respect of the Cooperation Business as and when appropriate.

REASONS FOR AND BENEFITS OF THE COOPERATION

The Board believes that the entering into of the Strategic Cooperation Memorandum between the Group and Sikula will benefit the Group in developing ginseng plantation and deep processing business of ginseng. Such business activities will enhance the Group's financial performance and profitability. The Board considers that the development of new business activities would be in the interests of the Company and its shareholders as a whole.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, Sikula and its ultimate beneficial owner(s) are third parties independent of the Company and its connected person(s) within the meaning ascribed thereto under the Rule Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors of the Company are reminded that the matters contemplated under the Strategic Cooperation Memorandum are still subject to the entering into of definitive agreements, and may or may not materialise as described or at all. Further announcement(s) will be made by the Company as and when appropriate to inform shareholders and potential investors of the Company of the further development of the Cooperation Business. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the Board
China Health Technology Group Holding Company Limited
Professor Fei Phillip
Chairman and Executive Director

Hong Kong, 16 May 2024

As at the date of this announcement, the Board comprises Professor Fei Phillip and Mr. Wang Yibin as the executive Directors; and Mr. Guo Zhonglong, Mr. Chau Wing Nam and Ms. Bu Xue as the independent non-executive Directors.

* *For identification purpose only*